HIGH-VOLUME · SEX-BALANCED

mirabegron Side Effects

mirabegron (also sold as Myrbetriq) is HIGH-VOLUME in this FAERS book #168 of 524 by FAERS report count. Signature opener: SEX-BALANCED - 67% of sex-coded reports are female (23,006 F / 11,471 M).

Data updated 2026-05-15

36,931
FAERS reports

FAERS voluntary reports, 2010 to 2025. High volume tracks exposure and reporting culture; see methodology for de-dup rules.

mirabegron reporting skew - 67% of sex-coded reports are female (23,006 F / 11,471 M). Volume band HIGH-VOLUME #168 of 524 by FAERS report count; caseload CASELOAD.

High-report extract for mirabegron (Myrbetriq): 36,931 FAERS rows (2010-2025). Top named reactions: FATIGUE, HEADACHE, DIZZINESS. Outcome stamps DEATH-HEAVY · HOSP-MID · SEX-BALANCED. FAERS is voluntary signal detection, not incidence.

Counts from the openFDA FAERS extract (2010–2025). Stamps CASELOAD · DEATH-HEAVY · HOSP-MID · SEX-BALANCED.

FATIGUE leads 2,215 of 36,931 reports

FATIGUE
2,215
HEADACHE
2,162
DIZZINESS
2,093
FALL
1,892
DIARRHOEA
1,861
PAIN
1,742
NAUSEA
1,705
INTENTIONAL PRODUCT MISUSE
1,524
HYPERTENSION
1,490
BLOOD PRESSURE INCREASED
1,474
ASTHENIA
1,468
ARTHRALGIA
1,391
RASH
1,350
DRY MOUTH
1,319
CONFUSIONAL STATE
1,308
CONDITION AGGRAVATED
1,297
DYSPNOEA
1,295
CONSTIPATION
1,292

Who reports · age peak 75+ (SEX-BALANCED)

Sex coding · SEX-BALANCED

Female 23,006 (66%)
Male 11,471 (33%)
Unknown 213

Age peak 75+ (8,928 reports)

0-17 446 (2%)
18-44 2,131 (10%)
45-64 4,175 (20%)
65-74 5,305 (25%)
75+ 8,928 (43%)

FAERS filings rising toward 2025

2010 2025

Reactions in Death Reports

Death-mentioned subset is HEAVY here (2,913 reports, 7.9%). Top co-reported reactions in that subset - voluntary, not causal.

Reaction Reports
DEATH 972
MATERNAL EXPOSURE DURING PREGNANCY 651
CONFUSIONAL STATE 647
PAIN 639
INFUSION RELATED REACTION 624
PEMPHIGUS 615
C-REACTIVE PROTEIN INCREASED 609
SYNOVITIS 601
PSORIATIC ARTHROPATHY 597
TYPE 2 DIABETES MELLITUS 596
GENERAL PHYSICAL HEALTH DETERIORATION 595
SYSTEMIC LUPUS ERYTHEMATOSUS 590
GASTROOESOPHAGEAL REFLUX DISEASE 585
PERICARDITIS 583
FOLLICULITIS 573
RASH 573
RHEUMATOID ARTHRITIS 573
GLOSSODYNIA 567

Reactions in Hospitalization Reports

Hospitalization mid-share (7,208, 19.5%). Co-reported reactions:

Reaction Reports
FALL 1,087
PAIN 868
FATIGUE 835
ASTHENIA 830
PNEUMONIA 827
CONFUSIONAL STATE 823
DIARRHOEA 758
NAUSEA 734
DYSPNOEA 709
RASH 701
HYPERTENSION 689
DIZZINESS 685
ARTHRALGIA 661
VOMITING 661
HEADACHE 635
INFUSION RELATED REACTION 622
GENERAL PHYSICAL HEALTH DETERIORATION 604
C-REACTIVE PROTEIN INCREASED 603
How to read mirabegron FAERS figures (CASELOAD · DEATH-HEAVY · HOSP-MID)

FAERS holds 36,931 voluntary reports linked to mirabegron (Myrbetriq), 2010-2025. Death is listed on 2,913 (7.9%). Hospitalization appears on 7,208 (19.5%). Top co-reported indication: Product Used For Unknown Indication.

CASELOAD books overweight common drugs and loud reporting cultures; SEX-BALANCED is the page opener, not a per-patient risk.

Read with mirabegron

Peers ranked by ABS(total_reports), then an ABS(death_share) pole; guide hop follows DEATH-HEAVY · HOSP-MID stamps.